- Conditions
- Major Depressive Disorder
- Interventions
- BHV-7000, Placebo
- Drug
- Lead sponsor
- Biohaven Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 62
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 54 more
Location Directory
Clinical trials in Jacksonville, Florida
This page shows live ClinicalTrials.gov search results for Jacksonville, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
7646
Shown on this page
12
Current sort
Recently updated
Location scope
Jacksonville, FL
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 709–720 of 7,646 matching trials in Jacksonville, FL.
Live ClinicalTrials.gov results.
Institutions in Jacksonville
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Bronchiectasis
- Interventions
- BI 1291583, Placebo matching BI 1291583
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 268 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 11
- States / cities
- Newport Beach, California • Sacramento, California • Gainesville, Florida + 8 more
- Conditions
- Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease
- Interventions
- Not listed
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 12,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1991 – 2034
- U.S. locations
- 86
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 65 more
- Conditions
- Secondary Immune Deficiency
- Interventions
- IgPro20
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 17
- States / cities
- Orange, California • Denver, Colorado • Coral Springs, Florida + 14 more
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Interventions
- WATCHMAN FLX LAAC Device, Non-Vitamin K Oral Anticoagulant
- Device · Drug
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 95
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 83 more
- Conditions
- Episodic Migraine
- Interventions
- Xeomin, Placebo
- Drug
- Lead sponsor
- Merz Therapeutics GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 997 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 47
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 43 more
- Conditions
- Chronic Migraine
- Interventions
- Xeomin, Placebo
- Drug
- Lead sponsor
- Merz Therapeutics GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 808 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 48
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 42 more
- Conditions
- Cardiovascular Disease and Lipoprotein(a)
- Interventions
- Pelacarsen (TQJ230)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 5,700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 120
- States / cities
- Andalusia, Alabama • Huntsville, Alabama • Mobile, Alabama + 101 more
- Conditions
- Breast Cancer
- Interventions
- LOXO-783, Fulvestrant, Imlunestrant, Abemaciclib, Anastrozole, Exemestane, or Letrozole, Paclitaxel
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 17
- States / cities
- Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 12 more
- Conditions
- Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Chest Radiography, Cisplatin, Computed Tomography, Echocardiography Test, Electronic Health Record Review, Fluciclovine F18, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, X-Ray Imaging
- Procedure · Drug · Other + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 67 more
- Conditions
- Fabry Disease
- Interventions
- Not listed
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 9,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2034
- U.S. locations
- 91
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 70 more
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Interventions
- Pelacarsen, Placebo, Inclisiran
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Sun City West, Arizona • Beverly Hills, California + 31 more